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Introduction 
The practice of extreme voluntary breath 
holding offers a unique opportunity to 
examine the physiologic responses to transient 
hypercapnic hypoxia. Breath holding of long 
durations (current world record is 11 min 35 s) 
in elite individuals produces blood gas partial 
pressures at the limits of human tolerance. The 
mediators underpinning maximal breath hold 
(BH) durations are undoubtedly integrative, 
involving not only severe changes in the 
partial pressures of arterial oxygen (PaO2) and 
carbon dioxide (PaCO2), but also lung and 
chemoreceptor afferents, and limitations 
in cerebral oxidative metabolism [1, 2]. We 
previously demonstrated the importance 
of increased cerebral blood flow (CBF) to 
maintain cerebral delivery of oxygen (CDO2) 
as arterial oxygen content (CaO2) decreases 
during apnea [3]. To mechanistically address 
this CBF compensation, the next logical step 
was to manipulate the CBF, and observe the 
consequence on maximal breath holding 
time. Efforts to describe the impact of CBF 
under acute hypoxic stress are fundamental 
for understanding pathology or circumstances 
of impaired CBF in hypoxia (e.g. with surgery, 
respiratory disease, and ischemic stroke). 
Acute hypoxia increases CBF [4]. While the 
mechanisms involved are complex (including 
the interplay between vasoactive agents, 
deoxyhemoglobin and PaCO2 [5]), it is likely 
that the CBF is targeted to maintain CDO2 
[6]. Indeed, in extreme breath holding (over 
5 min), PaO2 is reduced to about 4  kPa, but 
CDO2 never falls below resting baseline levels 
[3]. The corollary effect of increased CBF is 
greater washout of CO2 from brain tissue [7, 
8], and a consequent attenuation of central 
chemoreceptor stimulation, and ultimately 
the drive to breathe [9]. A reduced CBF may 
therefore reduce maximum BH duration not 
only by limiting CDO2, but also by augmenting 
brain tissue acidosis and the central drive to 
breathe. 
The purpose of this study was to 
determine the impact of a reduced CBF (via 
the non-selective cyclooxygenase inhibitor 
indomethacin) on maximal BH time in ultra-
elite apnea divers. The CBF, CDO2, PaO2 and 
PaCO2 were quantified. Ultra-elite apnea divers 
were utilized to limit variability associated with 
BH motivation, and to examine the most severe 
levels of combined hypoxia and hypercapnia 
achievable in unanesthetized humans. It was 
hypothesized that a reduction in CBF with 
Indo would decrease maximal BH duration, 
consequent to a reduced CDO2, and increased 
cerebral acidosis; i.e., reduced CO2 washout. 
Methods 
Participants and experimental design
This study was approved by the University 
of British Columbia Clinical Research Ethics 
Board, and the University of Split School of 
Medicine Ethics Board, and conformed to 
the declaration of Helsinki. Following written 
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The role of cerebral blood flow (CBF) on a maximal breath-hold (BH) in ultra-elite divers was examined. Divers (n 
= 7) performed one control BH, and one BH following oral administration of the non-selective cyclooxygenase 
inhibitor indomethacin (1.2 mg/kg). Arterial blood gases and CBF were measured prior to (baseline), and at BH 
termination. Compared to control, indomethacin reduced baseline CBF and cerebral delivery of oxygen (CDO2) 
by about 26% (p < 0.01). Indomethacin reduced maximal BH time from 339 ± 51 to 319 ± 57 seconds (p = 0.04). 
In both conditions, the CDO2 remained unchanged from baseline to the termination of apnea. At BH termination, 
arterial oxygen tension was higher following oral administration of indomethacin compared to control (4.05 ± 
0.45 vs. 3.44 ± 0.32 kPa). The absolute increase in CBF from baseline to the termination of apnea was lower with 
indomethacin (p = 0.01). These findings indicate that the impact of CBF on maximal BH time is likely attributable 
to its influence on cerebral H+ washout, and therefore central chemoreceptive drive to breathe, rather than to 
CDO2.
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informed consent, and consent to publish, 
seven ultra-elite apnea divers (one female and 
six male subjects, height (average ± standard 
deviation): 182 ± 9 cm, weight: 79 ± 13 kg, age: 
30 ± 6 years) volunteered from the Croatian 
National Apnea Team. Caffeine, alcohol and 
strenuous exercise were avoided 24 h before 
experimental testing. All participants arrived to 
the laboratory in the morning after consuming 
a light breakfast (toast and orange juice). 
Subjects completed two maximal dry supine 
apneas on the same day. The first apnea acted 
as the control condition (Control). Immediately 
following the control apnea, 1.2  mg/kg body 
weight of oral indomethacin (Indo) was 
administered. Following a 90-min break to 
assure peak effect of Indo [10], the second, 
experimental, apnea was performed. Identical 
preparatory procedures (practice sub-maximal 
breath holds, mild hyperventilation) were 
performed before each maximal apnea [3]. 
Arterial blood samples
A 20-gauge radial arterial catheter (Arrow, 
Markham, Ontario, Canada) was placed in the 
right radial artery. The catheter was attached to 
an in-line waste-less sampling system (Venous 
Arterial blood Management Protection System, 
VAMP, Edwards Lifesciences, Irvine, CA, USA). 
Blood samples (2 mL) were collected 30 sec prior 
to commencing the apnea, and immediately 
at apnea termination. Arterial PO2, PCO2, O2 
saturation (SaO2%), and pH were measured 
immediately using a commercially available 
blood gas analyzer (ABL90 Flex, Radiometer 
Medical, Brønshøj, Denmark). Oxygen content 
was calculated from Equation 1: 
               
    
   
             
Where; CaO2 is in mL/dL, Hb is in g/dL, PaO2 
in kPa, and SaO2 in %
Cerebrovascular measures
Blood flow through the right internal carotid 
artery (QICA) was measured using duplex 
ultrasound, with concomitant measures of vessel 
diameter and velocity. Blood flow was quantified 
offline using edge detection software [11]. The 
latter stages of an extreme maximal apnea elicit 
strong inspiratory muscle contractions and 
contractions of the sternocleidomastoid muscles 
that, in some, prevented reliable recordings 
of QICA. As such, a transcranial Doppler probe 
(Spencer Technologies, Redmond, WA, USA) was 
fixed on the temporal window for continuous 
measures of middle cerebral (MCAv) and 
posterior cerebral artery (PCAv) blood velocity. 
End apnea QICA in all participants was therefore 
calculated by multiplying baseline QICA with 
the percent change in middle cerebral artery 
velocity from baseline to end apnea. ICA and 
MCA have previously been shown to follow the 
same pattern of change during maximal apnea. 
The CDO2 was measured as oxygen content (Eq. 
1) multiplied by the QICA. Measures for QICA 
and PCAv were subsequently used to describe 
the responses in anterior and posterior CBF, 
respectively. 
Statistical methods
All values are presented as mean ± standard 
deviation. Absolute values for blood gases, 
pH, CDO2, QICA and PCAv between Indo and 
Control were compared using a priori paired 
single-tailed T-tests. The change in QICA and 
PCAv from baseline to end apnea between 
Indo and Control was also compared using a 
paired single-tailed T-test. When significance 
was reached, effect size is shown using Cohen’s 
d (d). Significance was set at 95% certainty (α 
of 0.05).
Results
Maximal apnea time was significantly reduced 
with Indo (319 ± 57 s) compared to Control 
(339 ± 51 s), p = 0.04, d = 0.39 (Fig. 1).
Arterial blood gases
Absolute values for PaO2, PaCO2, SaO2 and pH 
during Indo and Control for baseline and end of 
apnea are presented in Table 1. There were no 
significant differences in any blood gas variable 
at baseline between Indo and Control. In 
contrast, the PaO2 and SaO2 were significantly 
higher at the end of apnea during the Indo 
compared to Control trial (p < 0.01, d = -1.67, 
and p < 0.01, d = -1.45, respectively). There was 
no significant difference in PaCO2 at the end 
of apnea between Indo compared to Control 
(p = 0.11).
Cerebrovascular measures
The absolute change from baseline to end 
apnea in QICA and PCAv for Indo and Control 
are presented in Figure 2. Baseline QICA and 
PCAv was decreased by 26 ± 16% (d = 1.14) 
and 22 ± 14% (d = 1.07), respectively, with 
Indo compared to Control (p < 0.01 for both). 
Likewise, the CDO2 at baseline was reduced 
by 26 ± 16% with Indo compared to Control 
(p < 0.01, d = 1.34). At the end of apnea, absolute 
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QICA and PCAv were lower by 27 ± 16% 
(d = 1.46) and 24 ± 6% (d = 1.64), respectively, 
during Indo compared to Control (p < 0.01 
for both). The CDO2 at the end of apnea was 
14 ± 22% lower with Indo compared to Control 
(non-significant; p = 0.07, d = 0.73). Within 
condition, there was no significant change in 
CDO2 from baseline to end apnea, for Control 
and Indo (p > 0.05 for both).
The relative increase in QICA (Indo: 101 ± 
29%, Control: 103 ± 30%) and PCAv (Indo: 
109 ± 37%, Control: 114 ± 49%) from baseline 
to end apnea was similar with Indo compared 
to Control (p = 0.44 and p = 0.35, respectively). 
However, the absolute increase in QICA (Indo: 
156 ± 54 ml∙min-1, Control: 210 ± 32 ml∙min-1) 
and PCAv (Indo: 28 ± 8 cm∙sec-1, Control: 
37 ± 9 cm∙sec-1) was significantly lower with Indo 
compared to Control (p = 0.01, d = 1.32, and 
p < 0.01, d = 1.00, respectively), see Figure 2. 
Accounting for differences in BH lengths, the 
relative change from baseline to end apnea 
per unit time in QICA (Indo: 19.6 ± 6.8 %·min-1, 
Control: 18.3 ± 4.9 %·min-1) and PCAv (Indo: 
20.9 ± 7.1 %·min-1, Control: 19.9 ± 7.9 %·min-
1) was similar with Indo compared to Control 
(p > 0.05 for both). In contrast, the absolute PCAv 
change from baseline to end apnea per unit 
time was lower in Indo (5.5 ± 2.0 cm·s-1∙min-1) 
compared to Control (6.6 ± 1.8 cm·s-1∙min-1; 
p = 0.01, d = 0.58). The absolute QICA change 
from baseline to end apnea per unit time 
also trended to be lower with Indo (31.1 ± 
15.2 ml·min-1∙min-1) compared with Control 
(37.7 ± 6.8 ml·min-1∙min-1; p = 0.07).
Discussion
This study demonstrates that Indo attenuates 
CBF resulting in a moderate reduction of 
maximal BH tolerance. Given that CDO2 at 
baseline did not differ from CDO2 at end-apnea 
in both Indo and Control trials, the reduced 
maximal BH following CBF attenuation is likely 
not related to CDO2, and likely more related 
to the decreased cerebral CO2 washout, and 
therefore cerebral acidosis at the level of 
the central chemoreceptors leading to an 
augmented drive to breathe. Indeed, the 
tolerable level of hypoxemia (SaO2) was about 
9% higher during the Indo, compared to the 
Control apnea. 
What determines the apnea 
breakpoint?
The mechanisms of BH breakpoint have 
been topic of several reviews (e.g. [2, 12, 
13]). As described by Mithoefer in 1965 [14], 
the physiological apnea breakpoint, that is, 
the point of involuntary contraction of the 
Table 1. Arterial partial pressures of O2 (PaO2) and CO2 (PaCO2), arterial oxygen saturation in hemoglobin (SaO2), pH, and the cerebral oxygen delivery (CDO2) at baseline (BL) 
and end (End) of a maximal apnea with (Indo) and without (Control) administration of indomethacin. 
PaO2 (kPa) PaCO2 (kPa) SaO2  (%) pH CDO2 (ml/min)
Control
BL 14.16 ± 1.89 4.73 ± 0.83 98.7 ± 0.8 7.47 ± 0.05 44.4 ± 9.4
End 3.44 ± 0.32 7.28 ± 0.77 49.7 ± 6.8 7.35 ± 0.04 44.9 ± 8.0
Indo
BL 13.96 ± 2.0 4.60 ± 0.73 98.5 ± 0.9 7.46 ± 0.05 32.8 ± 9.3*
End 4.05 ± 0.45* 7.00 ± 0.83 59.3 ± 7.5* 7.34 ± 0.03 38.4 ± 11.0
* denotes a p < 0.05 between Indo and Control
Figure 2. Absolute change in internal carotid artery flow (QICA; left panel) and posterior cerebral artery velocity (PCAv; right panel) from baseline to the end of the breath 
hold during Control and Indo. 
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inspiratory muscles, is undoubtedly governed 
from a combination of factors – e.g., phrenic, 
glossopharyngeal, and central chemoreceptor 
afferents [1, 2, 15]. This breakpoint derives from 
general discomfort and an increased drive to 
breathe, but is overcome in the ultra-elite where 
voluntary maximal BH is often extended until 
unconsciousness (a grounds for disqualification 
in regulated competitions). We have previously 
demonstrated that the motivated physiological 
breakpoint in the ultra-elite generally falls 
at a critical PaO2 (of ~4  kPa) [1], and is likely 
governed in large part by consciousness. 
Nevertheless, given that CDO2 was maintained 
and PaO2 was lower at the termination of the 
Control compared to Indo apnea, the disparate 
apnea breakpoint in the current study is likely 
reflective for an additional role of central 
chemoreception when CBF and its reactivity to 
elevations in PaCO2 is impaired. 
Cerebral blood flow and CO2/H+ 
‘washout’
By administering Indo, the central drive to 
breathe was likely increased via reductions 
in the CBF response to apnea, which reduces 
CO2/H
+ washout from the medulla and in 
turn decreases pH [[7, 8] and see Fig 7. in [9]]. 
Theoretically, in a closed system independent 
of metabolism, flow equivalent to three times 
cerebral blood volume must pass through the 
cerebral vasculature for cerebral CO2 to reach 
95% equilibrium between arterial and tissue 
compartments with a steady state step increase 
in CO2 [see discussion in [16]]. Therefore, 
while true equilibrium is never reached in 
vivo, CBF will dictate the magnitude of partial 
equilibration (i.e., tissue-arterial gradient). 
The average 24% reduction in posterior CBF 
(PCAv) with Indo compared to Control would 
have thus increased the time constant for CO2 
tissue/arterial equilibrium in the brainstem by 
~24%, meaning that the magnitude of partial 
equilibrium would be reduced. In turn, despite 
the ~0.27 kPa higher PaCO2 at the termination 
of the Control vs. Indo apnea (related to 
the longer apnea time), it is likely that the 
reduced CO2 washout with Indo would have 
more than offset the slight difference in PaCO2 
so that cerebral tissue pH would have been 
comparable. 
Limitations
Due to the extended half-life of indomethacin 
(~4.5 h), we were unable to counter-balance 
the order of Indo vs. Control breath holds. 
Nevertheless, as confirmed in a previous 
counter balanced design [1], it is unlikely that 
an order effect would have influenced the 
present data. Moreover, maximal breath hold 
time is in fact increased with consecutive 
holds (the rationale for preparatory breath 
holds), therefore, had an order effect occurred, 
it would have confounded the data in the 
opposite direction of our primary finding; 
i.e., of a reduced maximal breath time hold 
following Indo. Each BH (Indo and Control) was 
performed following an identical preparatory 
phase (practice apneas), and ample recovery 
time (>90 min) was allocated between trials. 
We decided not to perform a second day 
placebo group to avoid multiple arterial 
catheterizations. 
Indomethacin reduces cerebrovascular 
reactivity to CO2 across the anterior and 
posterior circulation [9, 17] as well as cerebral 
O2 reactivity in the posterior circulation [9]. 
Although we were unable to measure blood 
flow in the vertebral artery, we observed an 
attenuated increase in absolute PCAv per 
unit time throughout the BH in the Control 
compared to the Indo condition. This finding 
supports the notion of reduced brainstem 
blood flow [9], and therefore CO2/H
+ washout 
at the level of the central chemoreceptors. 
Conclusion
We have previously demonstrated that a 
threshold PaO2 of just below 4 kPa likely 
underscores the BH breakpoint in elite apnea 
divers [1]. The results from the present study 
extend these findings by suggesting that, when 
CBF and its reactivity is impaired, the reduced 
BH time is unrelated to cerebral O2 delivery per 
se. In turn, we suggest the moderately reduced 
BH time is consequent to a reduced cerebral 
CO2 / pH washout, and therefore increased 
central drive to breathe. Together, the results 
from this study highlight the multi-faceted 
nature of the BH breakpoint in ultra-elite apnea 
divers, and the influence of CBF in the extreme 
drive to breathe. 
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